Lineage Cell Therapeutics, Inc. - LCTX Company Cumulative Debt

Lineage Cell Therapeutics specializes in developing innovative tissue regeneration methods. This market valuation chart reflects a specific debt level of 0.00. The business operates an advanced cellular restoration system for vision and spinal cord repair, creating unique ways to combat paralysis. Scaling Phase II trials with the support of major pharma partners serves as a key driver, while current costs are already priced in.

Company Aggregate Debts: Lineage Cell Therapeutics (LCTX) for 07/04/2022 - 10/28/2026

Metric breakdowns and analytics for Lineage Cell Therapeutics, Inc. (LCTX)

- price and consensus price forecast:

Price Lineage Corp|LCTX - Analyst Consensus Forecast

- market capitalization data:

Market Value Lineage Bio|LCTX - Total Company Value

- book capitalization data:

Accounting Value per Share Lineage Cell Therapeutics|LCTX - Book Capitalization|Market Cap to Net Assets Ratio lineagecell.com|LCTX - Company Total Assets

- debt and liquidity data:

Debt to Capital Lineage Cell Therapeutics|LCTX - Long-Term Debt to Equity|Short-Term Debt to Equity Lineage Cell Therapeutics Inc|LCTX - Company Debts|Debt to Book Capitalization Ratio Lineage Bio

Fundamental company analysis:Lineage Corp LCTX

Product sample of Lineage Cell Therapeutics Inc

This indicator reflects the total borrowed funds of the organization in real-time. The formula aggregates all credit obligations, allowing for an assessment of the cost of capital servicing amid changing market rates. An analysis of current debt obligations reveals risks of margin compression due to inflationary pressure. For Lineage Cell Therapeutics (LCTX), debt control is critical when financing OpRegen trials. Loan optimization ensures the company's stability until milestone payments are received from partners.

Key competitors